[go: up one dir, main page]

CL2007003467A1 - Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion - Google Patents

Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion

Info

Publication number
CL2007003467A1
CL2007003467A1 CL200703467A CL2007003467A CL2007003467A1 CL 2007003467 A1 CL2007003467 A1 CL 2007003467A1 CL 200703467 A CL200703467 A CL 200703467A CL 2007003467 A CL2007003467 A CL 2007003467A CL 2007003467 A1 CL2007003467 A1 CL 2007003467A1
Authority
CL
Chile
Prior art keywords
deacetilate
hdac
histone
administer
inhibitor
Prior art date
Application number
CL200703467A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003467(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2007003467A1 publication Critical patent/CL2007003467A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200703467A 2006-12-04 2007-12-03 Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion CL2007003467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86838806P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
CL2007003467A1 true CL2007003467A1 (es) 2008-07-11

Family

ID=39272127

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703467A CL2007003467A1 (es) 2006-12-04 2007-12-03 Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion

Country Status (25)

Country Link
US (1) US8093220B2 (es)
EP (1) EP2099451B1 (es)
JP (3) JP5784274B2 (es)
KR (1) KR101475538B1 (es)
CN (1) CN101553223A (es)
AR (1) AR064072A1 (es)
AU (1) AU2007328281B2 (es)
BR (1) BRPI0719746A2 (es)
CA (1) CA2670741C (es)
CL (1) CL2007003467A1 (es)
EC (1) ECSP099483A (es)
ES (1) ES2569477T3 (es)
GT (1) GT200900148A (es)
IL (1) IL198638A (es)
MA (1) MA30982B1 (es)
MX (1) MX2009005946A (es)
MY (1) MY148893A (es)
NO (1) NO20092473L (es)
PE (1) PE20081303A1 (es)
PL (1) PL2099451T3 (es)
RU (1) RU2469717C2 (es)
TN (1) TN2009000213A1 (es)
TW (1) TW200831075A (es)
WO (1) WO2008070011A2 (es)
ZA (1) ZA200903041B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2260020B1 (en) 2008-03-26 2014-07-23 Novartis AG Hydroxamate-based inhibitors of deacetylases b
AU2009270886A1 (en) * 2008-07-18 2010-01-21 Novartis Ag Use of HDAC inhibitors for the treatment of Hodgkin's disease
WO2010009285A1 (en) * 2008-07-18 2010-01-21 Novartis Ag Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
NZ707377A (en) * 2010-06-07 2015-09-25 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
RU2013114246A (ru) * 2010-09-01 2014-10-20 Новартис Аг Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
US9757385B2 (en) 2013-11-27 2017-09-12 Merck Sharp & Dohme Corp. Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
JP6723663B2 (ja) 2014-09-17 2020-07-15 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
KR20170124602A (ko) 2015-03-13 2017-11-10 포르마 세라퓨틱스 인크. Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CN1791396A (zh) * 2003-05-21 2006-06-21 诺瓦提斯公司 组蛋白脱乙酰基酶抑制剂与化疗剂的组合

Also Published As

Publication number Publication date
AU2007328281A1 (en) 2008-06-12
BRPI0719746A2 (pt) 2013-12-10
GT200900148A (es) 2011-08-02
KR101475538B1 (ko) 2014-12-22
TN2009000213A1 (en) 2010-10-18
ES2569477T3 (es) 2016-05-11
MY148893A (en) 2013-06-14
RU2009125439A (ru) 2011-01-20
CA2670741A1 (en) 2008-06-12
RU2469717C2 (ru) 2012-12-20
HK1132462A1 (zh) 2010-02-26
EP2099451A2 (en) 2009-09-16
MA30982B1 (fr) 2009-12-01
EP2099451B1 (en) 2016-02-10
PL2099451T3 (pl) 2016-07-29
MX2009005946A (es) 2009-06-17
NO20092473L (no) 2009-09-01
KR20090087115A (ko) 2009-08-14
WO2008070011A3 (en) 2008-07-24
WO2008070011A2 (en) 2008-06-12
IL198638A (en) 2015-06-30
CN101553223A (zh) 2009-10-07
CA2670741C (en) 2016-04-12
US20100069318A1 (en) 2010-03-18
AR064072A1 (es) 2009-03-11
JP5784274B2 (ja) 2015-09-24
JP2014097992A (ja) 2014-05-29
JP2016006070A (ja) 2016-01-14
IL198638A0 (en) 2010-02-17
TW200831075A (en) 2008-08-01
US8093220B2 (en) 2012-01-10
PE20081303A1 (es) 2008-10-28
AU2007328281B2 (en) 2011-03-31
ZA200903041B (en) 2010-03-31
JP2010511702A (ja) 2010-04-15
ECSP099483A (es) 2009-08-28

Similar Documents

Publication Publication Date Title
CL2007003467A1 (es) Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion
NO343834B1 (no) Farmasøytisk preparat omfattende en omega-karboksylarylsubstituert difenylurea for behandling av cancer
BRPI0721213A2 (pt) "regime de dosagem de inibidores da comt"
CL2007002686A1 (es) Compuestos derivados de 2h-isoquinolin-1-ona y 3h-quinazolin-4-ona, inhibidores de cinasa rho; y composicion farmaceutica, util para el tratamiento de una enfermedad o afeccion cardiovascular.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
GT200900065A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
DK2402317T3 (da) DGAT-inhibitor
GT200800151A (es) Inhibidores de 11-beta-hsd1
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2008000822A1 (es) Metodo para el tratamiento de la obesidad usando un inhibidor sglt2.
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
BRPI0818958A2 (pt) "processos para a fabricação dos hidrofluoroalquenos, para a fabricação dos hidrofluoroalcanóis, para a fabricação dos hidrofluoroésteres e composto"
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
CL2007003849A1 (es) Compuestos derivados de nafto[c]pirrol sustituidos con aminoacidos, utiles para tratar el cancer.
CL2007003176A1 (es) Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
NO20084803L (no) organiske forbindelser
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
BRPI0712902A2 (pt) compostos orgânicos
DK1989192T3 (da) 1,3-dioxane carboxylsyrer
CL2007002519A1 (es) Compuestos derivados de aminopiridina, inhibidores selectivo sobre aurora a; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos, utiles para inhibir el crecimiento de celulas tumoral
CL2007002479A1 (es) Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos.